Call for Abstract

11th Global Summit and Expo on Vaccines, Vaccination and Therapeutics, will be organized around the theme “To share the latest cutting-edge discoveries and emphasize current challenges in immunization ”

Vaccines usa 2016 is comprised of 24 tracks and 155 sessions designed to offer comprehensive sessions that address current issues in Vaccines usa 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Vaccines Against infectious diseases represent a grave threat to animal and human populations in terms of their impact on global health, agriculture and the economy. Vaccines developed for emerging infections in animals can protect animal health and prevent transmission of zoonotic diseases to humans. The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations.

  • Track 1-1Malaria vaccine
  • Track 1-2Measles Vaccines
  • Track 1-3Menactra Vaccine
  • Track 1-4Cholera Vaccine
  • Track 1-5Bordutella Vaccine
  • Track 1-6OPV Vaccine
  • Track 1-7Chickenpox Vaccine
  • Track 1-8Rubella Vaccine
  • Track 1-9Smallpox Vaccine
  • Track 1-10Meningococcal Vaccine
  • Track 1-11Pneumonia Vaccines
  • Track 1-12Food safety vaccines, glyco-conjugate vaccines
  • Track 1-13Emerging and re-emerging infectious disease vaccines
  • Track 1-14Vaccines against parasite infections
  • Track 1-15Antiviral and antibacterial vaccines
  • Track 1-16Biodefense vaccines: The filovirus experience
  • Track 1-17Advance in novel pertussis vaccines
  • Track 1-18Novel adjuvants
  • Track 1-19Plant and animal based vaccines
  • Track 1-20Biomarkers in vaccines
  • Track 1-21Rotavirus vaccines
  • Track 1-22Pneumococcal vaccines
  • Track 1-23H1N1 Vaccine

Cancer vaccines boost the immune system's natural ability to recognize and destroy things that are foreign and potentially harmful to the body. A strong, healthy immune system is able to identify antigens (substances on the surface of cells that are not normally part of the body) and attack them, typically eliminating them. The immune system is then left with a “memory” that helps it respond to those antigens in the future. A cancer treatment vaccine takes advantage of the immune system’s response to antigens. Often, cancer cells have specific molecules on their surface that are not present on healthy cells. When injected into a person, these specific molecules act as antigens, which stimulate the immune system to recognize and destroy cancer cells that have these molecules on their surface. Most cancer vaccines also contain adjuvants. cancer vaccines are two types they are Preventive (or prophylactic) vaccines.

  • Track 2-1Cancer Cell Biology, Diagnosis and Applied Research
  • Track 2-2Anti-cancer drugs and delivery
  • Track 2-3Novel Approaches to Cancer Therapeutics
  • Track 2-4Cancer Therapy and Clinical Cancer Research
  • Track 2-5Feline Leukemia Vaccines
  • Track 3-1Innate and acquired immunity, attenuated, conjugated, toxoid, and subunit vaccines
  • Track 3-2Vaccine vectors
  • Track 3-3Live attenuated, and killed vaccines
  • Track 3-4Vaccine efficiency and effectiveness
  • Track 3-5Edible Vaccines
  • Track 4-1Advances in HPV Vaccine
  • Track 4-2HPV Vaccines for Men
  • Track 4-3HPV Vaccine risks and controversies
  • Track 4-4HPV Vaccine for Women
  • Track 4-5Global HPV Vaccine Market Analysis
  • Track 4-6Childhood Travel Immunization
  • Track 5-1Animal flu-ecology
  • Track 5-2Strategies for Developing New Antiviral Flu Drugs
  • Track 5-3New Avenues for Influenza Control
  • Track 5-4Influenza vaccine Flu vaccine for nonhumans
  • Track 5-5Virology Vaccines
  • Track 5-6Veterinary Vaccines
  • Track 5-7Malaria vaccine
  • Track 5-8Swine Flu Vaccines
  • Track 5-9Yellow Fever Vaccines
  • Track 6-1Ebola Treatment
  • Track 6-2Anti Ebola Viral vaccines
  • Track 6-3Ebola Research
  • Track 6-4Animal Studies
  • Track 6-5Human Studies
  • Track 6-6Others
  • Track 7-1Immunization for Children
  • Track 7-2Infant Immunization scheduling
  • Track 7-3Passive Immunity
  • Track 8-1Vaccine development strategies for neurodegenerative disorders
  • Track 8-2New developments in veterinary vaccines
  • Track 8-3Vaccine approaches to immunotherapy and clinical trials
  • Track 8-4Nanotechnology in vaccine delivery
  • Track 8-5Novel discoveries in allergen vaccines
  • Track 8-6Advances in the delivery methods for transcutaneous immunization
  • Track 9-1Preclinical studies
  • Track 9-2Animal Models
  • Track 9-3Animal studies and research
  • Track 9-4Challenges in Animal studies
  • Track 9-5Report generation in Animalstudies
  • Track 9-6Others
  • Track 10-1Researches and support
  • Track 10-2Immunological sequences
  • Track 10-3Research and develpment
  • Track 10-4Modern Approaches
  • Track 10-5Immunological considerations
  • Track 10-6Others
  • Track 11-1Researches and Development
  • Track 11-2Immunological sequences
  • Track 11-3Modren Approches
  • Track 11-4Challenges in Emerging diseases
  • Track 11-5Immunological considerations
  • Track 11-6Infective Diseases
  • Track 12-1HIV research and therapy
  • Track 12-2Global HIV Vaccine Market Analysis
  • Track 12-3H1N1 Vaccine
  • Track 13-1New technologies
  • Track 13-2Innovation in rDNA Vaccines
  • Track 13-3New Recombinants Used
  • Track 13-4Recombinant Coding
  • Track 13-5Others
  • Track 14-1New technologies
  • Track 14-2Zika Vaccine Development
  • Track 14-3Polio Vaccines
  • Track 14-4Hepatitis Vaccines
  • Track 14-5Others
  • Track 15-1Nucleic Acids
  • Track 15-2DNA Vaccines Research
  • Track 15-3New Techniques
  • Track 15-4DNA Modifications
  • Track 15-5Others
  • Track 16-1Dibetic Immunization
  • Track 16-2Immunity Hyperactivity
  • Track 16-3Immunosupressing agents
  • Track 16-4New Vaccines
  • Track 16-5Others
  • Track 17-1New researches
  • Track 17-2Dental Vaccines
  • Track 17-3Development Of dental Vaccines
  • Track 17-4Dental Immunization Research
  • Track 17-5Others
  • Track 18-1Techniques for the multi-product vaccine
  • Track 18-2Robust and reproducible manufacturing techniques
  • Track 18-3QA/QC strategies in vaccine development and production
  • Track 18-4Technological improvements for downstream processing of vaccines
  • Track 18-5Generation of vaccines using high-throughput micro bioreactors
  • Track 18-6Mechanistic basic prophylactic and therapeutic vaccines
  • Track 18-7Vaccines Manufacturing Pharmaceuticals
  • Track 19-1Antibody therapy against viruses
  • Track 19-2Antiviral drug development and treatment strategies, including vaccination
  • Track 19-3Surveillance and Prevention
  • Track 19-4Travel Vaccine
  • Track 19-5MMR Vaccines
  • Track 20-1Cutaneous conditions
  • Track 20-2Heart Disorders Vaccines
  • Track 20-3Plant Disorders vaccines
  • Track 20-4Animal Disorders vaccines
  • Track 20-5Valvovaginal Disorders Vaccines
  • Track 20-6neurological Disorders
  • Track 20-7Intestinal Diseases
  • Track 20-8Eye Diseases and Disorders
  • Track 20-9Endocrine Diseases vaccines
  • Track 20-10Notifiable Diseases vaccines
  • Track 21-1Recombinant vaccines
  • Track 21-2Vaccination in pregnancy, newborns and the elderly populations
  • Track 21-3Molecular virology and immunology
  • Track 21-4Innate and Adaptive Immune Responses to Vaccination
  • Track 21-5Bacterial Vaccines
  • Track 22-1Peptide vaccines, DNA vaccines, cancer vaccines
  • Track 22-2Design and development of novel vaccines
  • Track 22-3Recombinant DNA vaccine technology
  • Track 22-4Polio vaccines, HIV vaccines
  • Track 22-5Development of vaccine for human papilloma virus
  • Track 22-6Carbohydrate / polysaccharide vaccine technology
  • Track 23-1Status and impact of childhood and adolescent immunizations
  • Track 23-2Vaccination in adults and older individuals: New perspectives
  • Track 23-3Travel immunizations and safety issues
  • Track 23-4Immunization in immunocompromised patients
  • Track 23-5Challenges in implementing immunization programs and improvement strategies
  • Track 24-1Vaccines Business Research
  • Track 24-2Business Plans
  • Track 24-3Approaches
  • Track 24-4 Global Plans in developing Business
  • Track 24-5Cost effective Business
  • Track 24-6Nano delivery Systems
  • Track 24-7Nano Formulations
  • Track 24-8Vaccines and Pharma Market